Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies
Episode 10 · Aug 15, 2025, 03:56 AM
Share
Subscribe
This article provides a comprehensive review of the latest clinical data supporting bispecific antibodies in lymphoma, their integration into earlier lines of therapy and combination regimens, and strategies for oncology pharmacists and managed care professionals to coordinate care and enhance patient safety.
To view the article and claim CE credit for this activity, click here.
Program Description
Bispecific antibodies (BsAbs) are revolutionizing the treatment of relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma by offering effective, off-the-shelf T-cell–redirecting therapies with manageable safety profiles. Pharmacists are integral in guiding treatment selection, supporting transitions of care, and contributing to the development of protocols and educational initiatives that ensure consistent, high-quality care across various institutions. This article provides a comprehensive review of the latest clinical data supporting BsAbs in lymphoma, their advantages over CAR T-cell therapies, and their integration into earlier lines of therapy and combination regimens. Best practices for managing unique toxicities, such as cytokine release syndrome, and coordinating care across inpatient and outpatient settings will also be discussed to equip oncology pharmacists and managed care professionals to optimize BsAb access, enhance patient safety, and improve cost-effectiveness.
Target Audience: Managed care pharmacists and oncology pharmacists
Type of Activity: Application
Release date: August 6, 2025
Expiration date: August 6, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Educational Objectives
At the completion of this activity, participants will be able to:
To view the article and claim CE credit for this activity, click here.
Program Description
Bispecific antibodies (BsAbs) are revolutionizing the treatment of relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma by offering effective, off-the-shelf T-cell–redirecting therapies with manageable safety profiles. Pharmacists are integral in guiding treatment selection, supporting transitions of care, and contributing to the development of protocols and educational initiatives that ensure consistent, high-quality care across various institutions. This article provides a comprehensive review of the latest clinical data supporting BsAbs in lymphoma, their advantages over CAR T-cell therapies, and their integration into earlier lines of therapy and combination regimens. Best practices for managing unique toxicities, such as cytokine release syndrome, and coordinating care across inpatient and outpatient settings will also be discussed to equip oncology pharmacists and managed care professionals to optimize BsAb access, enhance patient safety, and improve cost-effectiveness.
Target Audience: Managed care pharmacists and oncology pharmacists
Type of Activity: Application
Release date: August 6, 2025
Expiration date: August 6, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the recent clinical data for new and emerging indications that incorporate bispecific antibodies (BsAbs) in the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
- Explore the best practices for supporting transitions of care and ensuring safe and effective use of BsAbs in the treatment of lymphoma.
- Investigate innovative approaches in managed care to address logistical and operational hurdles, enabling broader access to BsAbs and improved clinical outcomes for patients.